Status:
RECRUITING
Skin-interfaced Colorimetric Bifluidic Sweat Sensor Device for the Diagnosis of Cystic Fibrosis (CF)
Lead Sponsor:
Milton S. Hershey Medical Center
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Cystic fibrosis (CF) is a multisystem autosomal recessive inherited disease affecting approximately 75,000 individuals in USA. The sweat chloride (Cl) test remains the gold standard for diagnosis of C...
Detailed Description
Background: Cystic fibrosis (CF) is a multisystem autosomal recessive inherited disease affecting approximately 75,000 individuals in USA. The sweat chloride (Cl) test remains the gold standard for di...
Eligibility Criteria
Inclusion
- adults 18 years of age or older capable of providing signed and dated informed consent,
- subjects with an established known diagnosis of cystic fibrosis (CF) or healthy volunteers,
- able to understand and speak English language.
Exclusion
- any medical condition or disorder known to potentially interfere with accurate measurements of sweat chloride
- inability to understand and speak the English language.
Key Trial Info
Start Date :
July 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05998629
Start Date
July 1 2024
End Date
December 1 2026
Last Update
January 9 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033